SCA
GILD icon

Stonebridge Capital Advisors’s Gilead Sciences GILD Stock Holding History

Stonebridge Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Sell
114,880
-6,857
-6% -$960K 1.12% 30
2025
Q4 		$14.9M Sell
121,737
-8,344
-6% -$1.01M 1.04% 32
2025
Q3 		$14.4M Sell
130,081
-9,029
-6% -$1.03M 1.03% 31
2025
Q2 		$15.4M Sell
139,110
-7,942
-5% -$845K 1.17% 26
2025
Q1 		$16.5M Sell
147,052
-47,122
-24% -$4.86M 1.34% 24
2024
Q4 		$17.9M Buy
194,174
+54,558
+39% +$4.91M 1.44% 20
2024
Q3 		$11.7M Buy
139,616
+4,752
+4% +$363K 0.95% 36
2024
Q2 		$9.25M Buy
134,864
+7,466
+6% +$498K 0.81% 41
2024
Q1 		$9.33M Buy
127,398
+9,263
+8% +$712K 0.84% 40
2023
Q4 		$9.57M Buy
118,135
+4,649
+4% +$362K 0.96% 38
2023
Q3 		$8.5M Buy
113,486
+3,413
+3% +$263K 0.94% 37
2023
Q2 		$8.48M Buy
110,073
+7,136
+7% +$569K 0.9% 37
2023
Q1 		$8.54M Buy
102,937
+3,728
+4% +$309K 0.97% 40
2022
Q4 		$8.52M Buy
99,209
+2,831
+3% +$224K 1.01% 38
2022
Q3 		$5.95M Sell
96,378
-437
-0.5% -$27.6K 0.77% 51
2022
Q2 		$5.98M Sell
96,815
-5,124
-5% -$317K 0.73% 53
2022
Q1 		$6.06M Buy
101,939
+79
+0.1% +$5.05K 0.65% 53
2021
Q4 		$7.4M Buy
101,860
+163
+0.2% +$11.2K 0.82% 48
2021
Q3 		$7.1M Sell
101,697
-91,176
-47% -$6.41M 0.86% 46
2021
Q2 		$12.9M Buy
192,873
+99,586
+107% +$6.65M 0.81% 48
2021
Q1 		$6.03M Sell
93,287
-8,260
-8% -$533K 0.8% 48
2020
Q4 		$5.92M Buy
101,547
+2,493
+3% +$150K 0.9% 44
2020
Q3 		$6.26M Sell
99,054
-702
-0.7% -$48.7K 1.12% 34
2020
Q2 		$7.67M Sell
99,756
-2,513
-2% -$193K 1.42% 21
2020
Q1 		$7.65M Buy
102,269
+354
+0.3% +$24.5K 1.61% 14
2019
Q4 		$6.62M Buy
101,915
+1,191
+1% +$77.6K 1.08% 35
2019
Q3 		$6.38M Buy
100,724
+4,127
+4% +$270K 1.1% 33
2019
Q2 		$6.53M Sell
96,597
-1,108
-1% -$72.9K 1.16% 30
2019
Q1 		$6.35M Buy
97,705
+11,797
+14% +$784K 1.18% 31
2018
Q4 		$5.37M Sell
85,908
-1,216
-1% -$85K 1.25% 31
2018
Q3 		$6.73M Buy
87,124
+3,485
+4% +$263K 1.35% 23
2018
Q2 		$5.92M Buy
83,639
+4,597
+6% +$325K 1.29% 26
2018
Q1 		$5.96M Buy
79,042
+2,754
+4% +$219K 1.37% 20
2017
Q4 		$5.46M Buy
76,288
+1,010
+1% +$76.7K 1.25% 24
2017
Q3 		$6.1M Buy
75,278
+1,335
+2% +$102K 1.5% 18
2017
Q2 		$5.23M Buy
73,943
+53,440
+261% +$3.56M 1.37% 22
2017
Q1 		$1.39M Sell
20,503
-849
-4% -$59.7K 0.38% 84
2016
Q4 		$1.53M Sell
21,352
-1,544
-7% -$115K 0.45% 77
2016
Q3 		$1.81M Buy
22,896
+325
+1% +$26.4K 0.57% 61
2016
Q2 		$1.88M Sell
22,571
-338
-1% -$30K 0.64% 59
2016
Q1 		$2.1M Buy
22,909
+255
+1% +$23K 0.74% 50
2015
Q4 		$2.29M Buy
22,654
+269
+1% +$28K 0.84% 43
2015
Q3 		$2.2M Buy
+22,385
New +$2.49M 0.88% 44

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Stonebridge Capital Advisors's GILD Position: Q1 2026 in Review

Stonebridge Capital Advisors reduced its Gilead Sciences (GILD) stake by 5.6% in Q1 2026, selling an estimated $960K and leaving 114,880 shares worth $16M. The position accounts for 1.12% of the portfolio, ranked #30.

Stonebridge Capital Advisors first reported a position in GILD in Q3 2015 and has held it in 43 quarters since. The position peaked at $17.9M in Q4 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Stonebridge Capital Advisors held 114,880 shares of Gilead Sciences worth $16M as of Q1 2026.
  • Stonebridge Capital Advisors sold 6,857 Gilead Sciences shares in Q1 2026, an estimated $960K.
  • Gilead Sciences made up 1.12% of Stonebridge Capital Advisors's portfolio in Q1 2026, its #30 holding.
  • Stonebridge Capital Advisors first reported a position in Gilead Sciences in Q3 2015 and has held it in 43 quarters since.
  • Stonebridge Capital Advisors's Gilead Sciences position peaked at $17.9M in Q4 2024.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Stonebridge Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.